Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.
Aleksandra Berkan-KawińskaAnna PiekarskaEwa JanczewskaBeata LorencMagdalena Tudrujek-ZdunekKrzysztof TomasiewiczHanna BerakAndrzej HorbanDorota Zarębska-MichalukPaweł PabjanIwona BuczyńskaMonika Pazgan-SimonDorota DybowskaWaldemar HalotaMałgorzata PawłowskaJakub KlapaczyńskiWłodzimierz MazurAgnieszka Czauż-AndrzejukŁukasz SochaŁukasz LauransAleksander GarlickiMarek SitkoJerzy JaroszewiczJolanta CitkoBeata DobrackaRafał KrygierJolanta Białkowska-WarzechaOlga TroninaTeresa Belica-WdowikBarbara Baka-ĆwierzRobert FlisiakPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Despite higher frequency of AE and treatment modifications, once completed, DAAs yield comparable results for patients with decompensated and compensated cirrhosis. High rate of serious adverse events in patients with advanced liver disease treated with PI may not be related to the detrimental effect of the medications, but rather to the disease itself.